Subscribe to RSS
DOI: 10.1055/s-0028-1103115
© Georg Thieme Verlag Stuttgart · New York
Kognitive Verhaltenstherapie bei Schizophrenie – Wirksamkeit bei antipsychotikarefraktärer Positivsymptomatik
Cognitive behavior therapy for patients with schizophrenic disorder – Efficacy in antipsychotic–resistant positive symptomsPublication History
Publication Date:
05 November 2008 (online)
![](https://www.thieme-connect.de/media/psychoneuro/200810/lookinside/thumbnails/10.1055-s-0028-1103115-1.jpg)
20–25 % der Patienten mit Schizophrenie leiden an einer persistierenden Positivsymptomatik, die auch durch neue atypische Antipsychotika nicht zufriedenstellend behandelbar ist. Deshalb werden in der medikamentösen Therapie zunehmend Kombinationen eingesetzt, die synergistische positive Effekte auf die Wahnsymptomatik haben und deren Nebenwirkungen antagonistisch sind. Neben der medikamentösen Therapie gewinnt die kognitiv–behaviorale Therapie an Bedeutung. Ziel der kognitiven Verhaltenstherapie ist nicht die Symptomfreiheit, sondern ein verbesserter Umgang des Patienten mit der Symptomatik.
20 to 25 % of schizophrenics suffer from a persistently positive pattern of symptoms which cannot be satisfactorily treated even with novel atypical neuroleptic agents. Hence, combinations are being increasingly used which exercise synergistically positive action on the manic symptoms and whose side effects are antagonistic. Alongside drug therapy increasing importance is attached to cognitive behavioural therapy. Behavioral therapy does not aim at complete freedom from all symptoms but rather at an improved attitude of the patients to their pattern of symptoms.
Key words
Cognitive therapy - behavior therapy - delirious - hallucinations –schizophrenia - psychosis
Literatur
- 1 Appelbaum PS, Robbins PC, Vesselinov R.. Persistence and stability of delusions over time. Compr Psychiatry. 2004; 45 317-324
- 2 Assion HJ, Reinbold H, Lemanski S. et al. . Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double–blind, placebo–controlled trial. Pharmacopsychiatry. 2008; 41 24-28
- 3 Beck AT, Rector NA.. Cognitive therapy of schizophrenia: a new therapy for the new millennium. Am J Psychother. 2000; 54 291-300
- 4 Garety PA, Freeman D, Jolley S. et al. . Reasoning, emotions, and delusional conviction in psychosis. J Abnorm Psychol. 2005; 114 373-384
- 5 Harrow M, Herbener ES, Shanklin A. et al. . Followup of psychotic outpatients: dimensions of delusions and work functioning in schizophrenia. Schizophr Bull. 2004; 30 147-161
- 6 Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C.. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst 2004
- 7 Malmberg L, Fenton M.. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2001
- 8 Penn DL, Waldheter EJ, Perkins DO. et al. . Psychosocial treatment for first–episode psychosis: a research update. Am J Psychiatry. 2005; 162 2220-2232
- 9 Tarrier N.. Cognitive behaviour therapy for schizophrenia – a review of development, evidence and implementation. Psychother Psychosom. 2005; 74 136-144
- 10 Vauth R, Stieglitz RD.. Chronisches Stimmenhören und persistierender Wahn. Göttingen: Hogrefe 2007
Korrespondenz
PD Dr. med. Dipl.–Psych. Roland Vauth
Psychiatrische Poliklinik Universitätsspital Basel
Claragraben 95
4005 Basel (Schweiz)
Email: rvauth@uhbs.ch